SYRS News and Press, Syros Pharmaceuticals Inc. From 12/08/19

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has discovered and validated a novel fetal hemoglobin repressor, Nuclear Factor I X (NFIX), using its gene control platform. The finding sheds light on h...

CAMBRIDGE, Mass. , Dec. 2, 2019 /PRNewswire/ --  Flagship Pioneering  has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that is redefining the powe...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Jaffray 31 st Annual Healthcare Conference. Details are...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the company and its collaborators from the Whitehead Institute for Biomedical Research will present on the identification of core drivers of metastasis in t...

Image source: The Motley Fool. Syros Pharmaceuticals, Inc.   (NASDAQ: SYRS) Q3 2019 Earnings Call Nov 12, 2019 , 8:30 a.m. ET Operator Continue reading

Syros Pharmaceuticals, Inc. (SYRS) Q3 2019 Earnings Conference Call November 12, 2019 8:30 AM ET Company Participants Naomi Aoki – Vice President-Corporate Communications and Investor Relations Nancy Simonian – Chief Executive Officer David Roth – Chief Medic...

Syros Pharmaceuticals (NASDAQ: SYRS ): Q3 GAAP EPS of -$0.47 beats by $0.01 . More news on: Syros Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Presented New Clinical Data from Phase 2 Study of SY-1425 in RARA-Positive Newly Diagnosed Unfit AML Patients at ESH Conference Presented New Preclinical Data on SY-5609 at AACR-NCI-EORTC Conference On Track for Key 2020 Milestones, Including Potential Proof-of-Concept Data for...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present on its identification and validation of a novel fetal hemoglobin repressor in an oral presentation at the 61 st American Society of Hematol...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2019 to report its third quarter 2019 financial results and provide...